The research study is testing a new way of taking hormone tablets for prostate cancer. The new method is called ‘adaptive therapy,’ also known as a pause/restart strategy.

Trial Status
Trial Phase
Phase 2 Drug Trial
Registry Listing
ERM Project ID
Trial contact details
Contact Person
Caitlin Bennett
What you need to know

Who can take part?

Patients with Castrate Resistant Metastatic prostrate cancer.

What is involved for you?

Your doctor will prescribe  a hormone tablet for your prostate cancer. There are two similar but slightly different tablets available – abiraterone (Zytiga®), which is taken as two tablets daily (500mg each) and enzalutamide (Xtandi®), which is taken as four capsules daily (40mg each).  You will also be asked to continue your regular hormonal injections (androgen deprivation therapy (ADT)) as per your standard treatment. Half of all participants in this trial will take their hormone tablet in the standard fashion. Half will take breaks in treatment when a blood test shows that the tablets have worked to control the cancer. You will see the doctor and study nurse every four weeks for a physical exam and blood test. This blood test will monitor how the treatment is working with a PSA blood test.

All research clinical trials news

Jan Mundt had just celebrated the birth of her first grandchild when she received a devastating cancer diagnosis. Despite having never smoked, Mrs Mundt was told a pain in her chest was being...



Clinical trials help gran defy terminal lung cancer diagnosis

A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.



Technology shines a light on better bladder cancer detection

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.



Highlighting Mater Research’s year of achievements: 2023 Annual Report

Displaying results 1-3 (of 20)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|